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(JOT ) is the only international journal
that specializes in orthopaedic trans-
lational medicine currently available in
the medical community, supported by
an international editorial board
composed of individuals from various
medical subspecialities, yet with
expertise in both basic and clinical as-
pects of the musculoskeletal sciences.JOT provides a “home” for the international orthopae-
dic community to share innovations and advancement in
both academic and industrial collaborations. JOT also
provides support for clinical and translational researchers
in data sharing, adoption of good laboratory and clinical
practices, and effective use of informatics. JOT is there-
fore the journal to meet our current and future health
challenges in musculoskeletal and related systems, focus-
sing research efforts findings into the early diagnosis,
prevention, treatment, and rehabilitation of musculoskel-
etal disorders.
JOT is managed by both the Chinese Speaking Ortho-
paedic Society and the International Chinese Musculoskel-
etal Research Society (ICMRS), which are sister societies
and partners devoted to scientific and clinical research with
translational potential over the past two decades, since
their very inception.
About translational research/translational
medicine/orthopaedic translation
There are many definitions concerning “Translational
research,” but all share consensus on a broad and inclu-
sivedrather than restrictiveddefinition [1,2]. Orthopae-
dic translation is a branch of Translational Medicine under
the umbrella of Translation Research that deals with the
process of transforming, not only laboratory discoveries
into new therapies for patients, but also observations
from the bedside for scientific validation and further
improvement of clinical applications, generally known as
“two-way traffic,” which include “from bench to bedside016/j.jot.2013.07.005
2013, The Author. Published by Elsevier (Singap
ecommons.org/licenses/by-nc-nd/4.0/).and/or community” and “from bedside to bench to
bedside/community [3,4].” In the past, the translational
process took a decade or more before scientific findings
from a research laboratory could be advanced through
preclinical and clinical studies to result in a new
regulatory-body-approved therapy or device for diagnosis,
prevention, and treatment. As an opinion-sharing plat-
form, the launch of JOT will function as a bridge to con-
nect various domains within the translational roadmap
and will accelerate the process or shorten the journey of
orthopaedic translation.
Initiation of orthopaedic translation
The United States has long been regarded a pioneer of
translational research. In order to address the need for
better integrated and focused clinical and translational
research support, the National Institute of Health (NIH)
launched a unique program that funds Institutional Clinical
and Translational Science Awards in 2006 to facilitate
collaborative research. Because orthopaedic or musculo-
skeletal research is highly translational, soon after the
launch of NIH’s initiative, the Orthopaedic Research Soci-
ety (ORS) published an editorial paper, “Translational
research: Whither the ORS?” in the Journal of Orthopaedic
Research in 2008 and subsequently initiated its own
translational roadmap with themes that parallel those of
the NIH [3]. The themes include the formation of inter-
disciplinary teams, a focus on specific musculoskeletal
diseases, interdisciplinary education, fostering trans-
lational career pathways, and established disease-oriented
and disease-specific clusters or interests groups targeting
the refractory chronic musculoskeletal diseases that pla-
gue our society, including osteoarthritis, osteoporosis,
intervertebral disk degeneration, degenerative tendinop-
athy, and periprosthetic osteolysis. Although there is no
national sponsored program in China, various clinical and
research institutions mobilized their own resources and
expertise to form around 50 centres labelled with “Trans-
lation Research” or “Translational Medicine” within the
past 5 years following the NIH or ORS developmentore) Pte Ltd. This is an open access article under the CC BY-NC-ND
4 Editorialpatterns, and subsequently published a first monograph on
translation medicine by Professor Dai Ke-rong, a leading
orthopaedic surgeon and clinical scientist in 2012 [5].
Mission and vision of JOT in orthopaedic
translation
The launch of JOT is a significant milestone in the interna-
tional orthopaedic community. As a scientific journal dealing
with translational medicine in musculoskeletal and related
fields, JOT covers scientific and regulatory investigations to
translate preclinical researches into clinical applications
with specific emphasis on, for example, new bio-
technologies, medical devices, biomaterials, bioengi-
neering, disease-specific biomarkers, cellular and molecular
medicine, genomics science, bioinformatics, applied immu-
nology,molecular imaging, drug discovery and development,
and last but not least, the regulation and health policies.
Papers accepted for publication by JOT will benefit and
improve novel diagnostics/prognostics and therapeutics for
clinical use, that is, will transform scientific discoveries
arising from laboratory, clinical, or population studies into
newclinical tools and applications that improve the health of
musculoskeletal and related human systems by reducing
disease incidence, morbidity, and mortality.
JOT welcomes the submission of high-quality manu-
scripts (original research papers, reviews, editorials, per-
spectives, and letters to the editors) in the field of
musculoskeletal and related fields, which meet the gen-
eral criteria of significance and scientific excellence,
including both preclinical and clinical research. Clinical
studies are encouraged for submission to JOT, including
randomized trials, intervention studies, studies of
screening and diagnostic tests, cohort studies, cost-
effectiveness analyses, caseecontrol studies, and surveys
with good response rates. Comparative studies with
available diagnostic tools and treatment methods or pro-
tocols and combination therapies for achieving better
treatment efficacy are also highly desirable especially
those with scientific discussion on obstacles present in
their translational process.
Unique presentation format of translational
research work
Formulation of research questions or study
objectives
Translational orthopaedic research is a two-way street with
respect to the formulation of research questions or study
objectives, that is, mechanistic hypothesis-driven research
(studies from bench to bedside) and clinical observation-
driven studies (investigations from bedside to bench);
however, the latter is normally excluded by purely scien-
tific journals.
Study design with positive control is appreciated
Comparative studies with current diagnostic, preventive,
and treatment protocols, drugs, biomaterials, or implants/devices, and even effective combination therapy are
encouraged to provide essential information regarding the
authors’ translational work and to prove its sustainability. As
highlighted in the Instructions to Authors of JOT, testing or
evaluation methods shall be standardized by referring to
those listed in the ISO and/or American Society for Testing
Materials (ASTM) whenever possible, so that these studies
could be used directly as references for comparing findings
that were generated under the same or at least comparable
conditions for regulatory bodies or certified testing centres
of the Food and Drug Administration in the United States or
China Food and Drug Administration (CFDA) in China. This
standardization will certainly help shorten the regulatory
registration process. Combination therapy with better
treatment efficiency, safety, and cost-effectiveness are also
in the interests of JOT in its overall translational roadmap.
Discussion of obstacles in orthopaedic translation
JOT will be an effective platform to discuss obstacles and
suggest or find solutions toward an effective orthopaedic
translation. Therefore, JOT welcomes studies for estab-
lishing new regulatory guidelines that are not currently
available yet relevant with the potential for adaptation into
regulatory guidelines for accelerating clinical applications.
Such efforts may help overcome one of the important
regulatory burdens, that is, the balance between efficiency
and transparency of management.
Platform in orthopaedic education
JOT also has an educational mission to meet the demands
of maintaining or expanding the biomedical workforce and
education programs that attract and retain young people
in the translational and biomedical sciences in musculo-
skeletal and related areas. Given the present scenario of
the scientific publishing market and the specificity of the
publication, JOT provides a platform for training programs
in translational research, and proposes and promotes ini-
tiatives that use new-generation interactive educational
tools, such as open Internet platform, to fulfil the unmet
need of disseminating new knowledge in clinical and
translational orthopaedics that can lead to a better clin-
ical practice. Education is a two-way street. Through
publication of translational work in JOT, clinicians, bi-
ologists, and engineers may develop and speak a common
language. This is particularly important for nonclinical
scientists who need to be educated in the language of a
clinician [4].
A bridge in translational orthopaedics with
social missions
Translational orthopaedics has both regulatory and commer-
cial implications innature.Withjournaldevelopment,wehope
that JOT would also be a platform to unite public, govern-
mental, academic, and industry interests in supporting the
publication of scientific papers that have an impact on accel-
erating and helping policy makers identify good topics, prod-
ucts, and regulations, and helping develop translationable
Editorial 5products, especially cost-effective and safe ones on top of
innovations in musculoskeletal and related medicine.
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